Seaside Therapeutics, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Cambridge MA United States (2005)
Status: Defunct (2014)

Organization Overview

First Clinical Trial
2008
NCT00788073
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2011

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

arbaclofen (9 trials)

Drugs in Phase 2 Trials (1)

stx107 (2 trials)

Drugs in Phase 1 Trials (1)

baclofen (lioresal) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Autism Spectrum Disorder (Phase 3)

Autistic Disorder (Phase 3)

Child Development Disorders, Pervasive (Phase 3)

Disease (Phase 3)

Fragile X Syndrome (Phase 3)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 12
  • # of Trial APIs: 3